HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has maintained a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but has lowered the price target from $42 to $41.
December 22, 2023 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Syndax Pharmaceuticals but reduces the price target from $42 to $41.
The reduction in price target is minor, suggesting that the analyst still sees potential in the stock but is slightly adjusting expectations. The Buy rating indicates a positive outlook, which could balance the impact of the lowered target. Therefore, the short-term impact on the stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100